189 related articles for article (PubMed ID: 18395459)
1. Tiagabine is neuroprotective in the N171-82Q and R6/2 mouse models of Huntington's disease.
Masuda N; Peng Q; Li Q; Jiang M; Liang Y; Wang X; Zhao M; Wang W; Ross CA; Duan W
Neurobiol Dis; 2008 Jun; 30(3):293-302. PubMed ID: 18395459
[TBL] [Abstract][Full Text] [Related]
2. Oral uridine pro-drug PN401 is neuroprotective in the R6/2 and N171-82Q mouse models of Huntington's disease.
Saydoff JA; Garcia RA; Browne SE; Liu L; Sheng J; Brenneman D; Hu Z; Cardin S; Gonzalez A; von Borstel RW; Gregorio J; Burr H; Beal MF
Neurobiol Dis; 2006 Dec; 24(3):455-65. PubMed ID: 17011205
[TBL] [Abstract][Full Text] [Related]
3. Altered selenium status in Huntington's disease: neuroprotection by selenite in the N171-82Q mouse model.
Lu Z; Marks E; Chen J; Moline J; Barrows L; Raisbeck M; Volitakis I; Cherny RA; Chopra V; Bush AI; Hersch S; Fox JH
Neurobiol Dis; 2014 Nov; 71():34-42. PubMed ID: 25014023
[TBL] [Abstract][Full Text] [Related]
4. Sertraline slows disease progression and increases neurogenesis in N171-82Q mouse model of Huntington's disease.
Duan W; Peng Q; Masuda N; Ford E; Tryggestad E; Ladenheim B; Zhao M; Cadet JL; Wong J; Ross CA
Neurobiol Dis; 2008 Jun; 30(3):312-322. PubMed ID: 18403212
[TBL] [Abstract][Full Text] [Related]
5. Degeneration of ipRGCs in Mouse Models of Huntington's Disease Disrupts Non-Image-Forming Behaviors Before Motor Impairment.
Lin MS; Liao PY; Chen HM; Chang CP; Chen SK; Chern Y
J Neurosci; 2019 Feb; 39(8):1505-1524. PubMed ID: 30587542
[TBL] [Abstract][Full Text] [Related]
6. Ectopic expression of the striatal-enriched GTPase Rhes elicits cerebellar degeneration and an ataxia phenotype in Huntington's disease.
Swarnkar S; Chen Y; Pryor WM; Shahani N; Page DT; Subramaniam S
Neurobiol Dis; 2015 Oct; 82():66-77. PubMed ID: 26048156
[TBL] [Abstract][Full Text] [Related]
7. Neuroprotective effects of PPAR-γ agonist rosiglitazone in N171-82Q mouse model of Huntington's disease.
Jin J; Albertz J; Guo Z; Peng Q; Rudow G; Troncoso JC; Ross CA; Duan W
J Neurochem; 2013 May; 125(3):410-9. PubMed ID: 23373812
[TBL] [Abstract][Full Text] [Related]
8. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease.
Southwell AL; Ko J; Patterson PH
J Neurosci; 2009 Oct; 29(43):13589-602. PubMed ID: 19864571
[TBL] [Abstract][Full Text] [Related]
9. Treatment with a herbal formula B401 enhances neuroprotection and angiogenesis in the R6/2 mouse model of Huntington's disease.
Wang SE; Lin CL; Hsu CH; Sheu SJ; Chien CT; Wu CH
Drug Des Devel Ther; 2015; 9():887-900. PubMed ID: 25733809
[TBL] [Abstract][Full Text] [Related]
10. Tiagabine, a GABA uptake inhibitor, attenuates 3-nitropropionic acid-induced alterations in various behavioral and biochemical parameters in rats.
Dhir A; Akula KK; Kulkarni SK
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):835-43. PubMed ID: 18234412
[TBL] [Abstract][Full Text] [Related]
11. Structural MRI detects progressive regional brain atrophy and neuroprotective effects in N171-82Q Huntington's disease mouse model.
Cheng Y; Peng Q; Hou Z; Aggarwal M; Zhang J; Mori S; Ross CA; Duan W
Neuroimage; 2011 Jun; 56(3):1027-34. PubMed ID: 21320608
[TBL] [Abstract][Full Text] [Related]
12. Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice.
Schilling G; Savonenko AV; Coonfield ML; Morton JL; Vorovich E; Gale A; Neslon C; Chan N; Eaton M; Fromholt D; Ross CA; Borchelt DR
Exp Neurol; 2004 May; 187(1):137-49. PubMed ID: 15081595
[TBL] [Abstract][Full Text] [Related]
13. Mutant huntingtin causes context-dependent neurodegeneration in mice with Huntington's disease.
Yu ZX; Li SH; Evans J; Pillarisetti A; Li H; Li XJ
J Neurosci; 2003 Mar; 23(6):2193-202. PubMed ID: 12657678
[TBL] [Abstract][Full Text] [Related]
14. Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.
Fatoba O; Kloster E; Reick C; Saft C; Gold R; Epplen JT; Arning L; Ellrichmann G
Exp Neurol; 2018 Apr; 302():112-128. PubMed ID: 29309751
[TBL] [Abstract][Full Text] [Related]
15. Small-molecule TrkB receptor agonists improve motor function and extend survival in a mouse model of Huntington's disease.
Jiang M; Peng Q; Liu X; Jin J; Hou Z; Zhang J; Mori S; Ross CA; Ye K; Duan W
Hum Mol Genet; 2013 Jun; 22(12):2462-70. PubMed ID: 23446639
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic effects of coenzyme Q10 and remacemide in transgenic mouse models of Huntington's disease.
Ferrante RJ; Andreassen OA; Dedeoglu A; Ferrante KL; Jenkins BG; Hersch SM; Beal MF
J Neurosci; 2002 Mar; 22(5):1592-9. PubMed ID: 11880489
[TBL] [Abstract][Full Text] [Related]
17. Lack of minocycline efficiency in genetic models of Huntington's disease.
Mievis S; Levivier M; Communi D; Vassart G; Brotchi J; Ledent C; Blum D
Neuromolecular Med; 2007; 9(1):47-54. PubMed ID: 17114824
[TBL] [Abstract][Full Text] [Related]
18. An independent study of the preclinical efficacy of C2-8 in the R6/2 transgenic mouse model of Huntington's disease.
Wang N; Lu XH; Sandoval SV; Yang XW
J Huntingtons Dis; 2013; 2(4):443-51. PubMed ID: 25062731
[TBL] [Abstract][Full Text] [Related]
19. Partial resistance to malonate-induced striatal cell death in transgenic mouse models of Huntington's disease is dependent on age and CAG repeat length.
Hansson O; Castilho RF; Korhonen L; Lindholm D; Bates GP; Brundin P
J Neurochem; 2001 Aug; 78(4):694-703. PubMed ID: 11520890
[TBL] [Abstract][Full Text] [Related]
20. Prevention of Huntington's Disease-Like Behavioral Deficits in R6/1 Mouse by Tolfenamic Acid Is Associated with Decreases in Mutant Huntingtin and Oxidative Stress.
Liu P; Li Y; Yang W; Liu D; Ji X; Chi T; Guo Z; Li L; Zou L
Oxid Med Cell Longev; 2019; 2019():4032428. PubMed ID: 31049134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
